Evidence map›Paper›PMID 32074279›Full record

ArticleBlood advances2020

Presentation of BK polyomavirus-associated hemorrhagic cystitis after allogeneic hematopoietic cell transplantation.

Hannah Imlay, Hu Xie, Wendy M Leisenring, Elizabeth R Duke, Louise E Kimball, Meei-Li Huang, Steven A Pergam, Joshua A Hill, Keith R Jerome, Filippo Milano and 5 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07638332 (A Single-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Adults), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07638332 phase1 / phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Single-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Adults

TypeinterventionalSponsorLucasBioRan2026 to 2028Enrolled42ConditionsHemorrhagic CystitisArmsLB-DTK-BKV, Standard-of-care
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Hemorrhagic cystitis in allogeneic stem cell transplantation: a role for age and prostatic hyperplasia.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Hannah ImlayFred Hutchinson Cancer Research Center, Seattle, WA.
Hu XieFred Hutchinson Cancer Research Center, Seattle, WA.
Wendy M LeisenringFred Hutchinson Cancer Research Center, Seattle, WA.
Elizabeth R DukeFred Hutchinson Cancer Research Center, Seattle, WA.
Louise E KimballFred Hutchinson Cancer Research Center, Seattle, WA.
Meei-Li HuangFred Hutchinson Cancer Research Center, Seattle, WA.
Steven A PergamFred Hutchinson Cancer Research Center, Seattle, WA.
Joshua A HillFred Hutchinson Cancer Research Center, Seattle, WA.
Keith R JeromeFred Hutchinson Cancer Research Center, Seattle, WA.
Filippo MilanoFred Hutchinson Cancer Research Center, Seattle, WA.
W Garrett NicholsChimerix Inc., Durham, NC.
Phillip S PangVir Biotechnology Inc., San Francisco, CA; and.
Hans H HirschTransplantation and Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Ajit P LimayeDepartment of Medicine, University of Washington, Seattle, WA.
Michael BoeckhFred Hutchinson Cancer Research Center, Seattle, WA.
University of Washington · USFred Hutch Cancer Center · USChimerix (United States) · USUniversity of Basel · CHVIR Biotechnology (United States) · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
NCCIH Supplement to NCATS/CTSA Program for KL2 Scholars - M. SoddersKL2TR002317 · NCATS · UNIVERSITY OF WASHINGTON · PI Christy Michelle McKinney · 2017 to 2026
$14.5M
Training Program in Infectious Diseases in the Immunocompromised HostT32AI118690 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2016 to 2025
$4.0M
Infections in Hematopoietic Cell Transplant RecipientsK24HL093294 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BOECKH, MICHAEL J · 2009 to 2019
$1.5M
Human Herpesvirus 6 in Lower Respiratory Tract Disease and Chromosomal Integration after Hematopoietic Cell TransplantationK23AI119133 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HILL, JOSHUA AIDEN · 2015 to 2019
$922k
NCATS NIH HHS KL2 TR002317NCI NIH HHS P30 CA015704NHLBI NIH HHS K24 HL093294NIAID NIH HHS HHSN272201100041CNIAID NIH HHS HHSN272201600016CNIAID NIH HHS HHSN272201600019CNIAID NIH HHS K23 AI119133NIAID NIH HHS T32 AI118690
6 · The paper itself

Abstract

BK polyomavirus (BKPyV) has been associated with hemorrhagic cystitis (HC) after allogeneic hematopoietic cell transplantation (HCT), but the natural history of HC and factors associated with the clinical course are incompletely understood. We retrospectively analyzed allogeneic HCT patients transplanted from 2007-2017 who presented after platelet engraftment or after day 28 post-HCT with BKPyV-associated HC (BKPyV-HC), which was defined as a positive urine BKPyV PCR, ≥1 plasma BKPyV viral load result, and macroscopic hematuria (Bedi grade ≥2). Factors associated with resolution of macroscopic hematuria and resolution of all cystitis symptoms within 90 days after HC diagnosis were investigated in multivariable models. In 128 patients with BKPyV-HC, the median times from diagnosis to resolution of all symptoms, macroscopic hematuria, and urinary clots (present in 55% [71/128]) were 24 days (15-44), 17 days (10-30), and 14 days (5-26), respectively. Ninety percent of patients had BKPyV viremia at the onset of HC with a median viral load of 1850 copies/mL (interquartile range, 240-8550). In multivariable models, high plasma viral load (≥10 000 copies/mL) and cytopenias at the beginning of BKPyV-HC were significantly associated with longer macroscopic hematuria and cystitis symptoms. Use of cidofovir was not associated with shorter duration of illness. In conclusion, BKPyV-HC after allogeneic HCT is characterized by prolonged and severe symptoms and requires improved management strategies. High-grade viremia and cytopenias were associated with a longer duration of BKPyV-associated HC. Accurate descriptions of disease and factors associated with prolonged recovery will inform end points of future clinical trials.

Indexed as

BK VirusCystitisHematopoietic Stem Cell TransplantationPolyomavirus InfectionsHumansRetrospective Studies

Identifiers

PMID32074279
PMCPMC7042995
OpenAlexW3006760370

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.